New Issue: March 35(3)
The March issue of RFS has published! The Editor’s Choice paper is: “Consumers as Financiers: Consumer Surplus, Crowdfunding, and Initial Coin Offerings” by Jeongmin Lee and Christine A Parlour
Forthcoming Paper
“Liquidation Cascade and Anticipatory Trading: Evidence from the Structured Equity Product Market” by Jun Kyung Auh and Wonho Cho
Spotlight: How Do Capital Requirements Affect Loan Rates? Evidence from High Volatility Commercial Real Estate
Regulatory capital requirements for banks have been a topic of heated discussions by academicians, bankers, and policy makers for decades. Central to these discussions is how costly requiring banks to fund themselves with more equity (rather than cheaper deposits) is and how these possible regulatory costs are transmitted to bank borrowers. In a recently published RCFS paper, “How Do Capital Requirements Affect Loan Rates? Evidence from High Volatility Commercial Real… Read More »Spotlight: How Do Capital Requirements Affect Loan Rates? Evidence from High Volatility Commercial Real Estate
Update to RFS Referee Payments
Beginning April 1, 2022, referees will no longer accrue a payment balance for RFS. Referees will be paid for each report rather than being paid after their accounts reach the threshold. Submitting authors will no longer be able to apply their reviewer account balances to pay submission fees beginning April 1.
Forthcoming Papers
“The Burden of the National Debt: Evidence from Mergers and Acquisitions” by Ruchith Dissanayake, Yanhui Wu, and Huizhong Zhang “Social Change through Financial Innovation: Evidence from Donor-advised Funds” by Jillian Grennan
Dual Submissions with RCFS Winter Conference
The dual submission decisions for the RCFS Winter Conference have been sent. If you submitted your paper as a dual submission and did not receive your decision email, please contact us.
RCFS Keynote Speaker
RCFS is pleased to announce that Tarun Ramadorai (Imperial College London) will be the RCFS Keynote Speaker at Cavalcade North America 2022. The keynote will take place on Monday, May 23.
Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing… Read More »Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
Forthcoming Paper
“Self-fulfilling Asset Prices” by Alexander K. Zentefis
Decisions for SFS Cavalcade North America 2022
The decisions for SFS Cavalcade North America 2022 have been sent. If you did not receive your decision, please contact us. We received 1433 submissions. The final program was highly selective, with an 9.4% acceptance rate. If you selected dual submission with RAPS or RCFS, you will receive a separate decision email from the journal in the next few weeks.